Market Overview

Goldman Sachs Places Centene EPS and PT Under Review

Share:
Related CNC
Medicare To Make 'Historic' Shift In Payments, Health Insurers Mixed
Sterne Agee: Tough Flu Season Helps Hospitals, Hurts Insurers
Can Aetna (AET) Maintain Its Earnings Streak This Season? - Analyst Blog (Zacks)

Goldman Sachs has published a research report on Centene (NYSE: CNC) commenting on lowered guidance from new market utilization pressures.

In the report, Goldman Sachs writes, "CNC revised its 2012 EPS guidance downwards, reflecting higher than anticipated medical costs in its new Texas and Kentucky markets, as well as for its individual commercial business (Celtic). CNC now sees 2012 EPS of $1.45-$1.65 vs. prior $2.64-$2.84 and anticipates a loss for 2Q2012. We expect CNC will provide further detail at its investor day this Thursday."

Goldman Sachs has EPS and price target for Centene under review, while the stock is trading down $9.27 from Friday's $35.47 closing price.

Latest Ratings for CNC

DateFirmActionFromTo
Jan 2015BarclaysMaintainsOverweight
Jan 2015Deutsche BankMaintainsHold
Jan 2015BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color News Guidance Reiteration Analyst Ratings

 

Related Articles (CNC)

Around the Web, We're Loving...

Get Benzinga's Newsletters